ArticleCureus2025
Primary Splenic Follicular Lymphoma Presenting As Isolated Splenomegaly: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is an indolent B-cell lymphoma that usually presents with lymph node enlargement; primary splenic involvement without nodal disease is exceedingly rare. We describe a woman in her late 60s with three months of early satiety, abdominal distension, and weight loss. Examination revealed massive splenomegaly without lymphadenopathy. Laboratory tests were largely normal aside from mild thrombocytopenia. Imaging positron emission tomography/computed tomography (PET/CT) demonstrated an fluorodeoxyglucose (FDG)-avid enlarged spleen with no other lesions. Bone marrow biopsy showed a benign-appearing lymphoid aggregate, and a definitive diagnosis could not be reached. The patient subsequently underwent splenectomy, and histopathology with immunohistochemistry confirmed WHO grade 2 FL confined to the spleen (Ann Arbor stage I). She was started on rituximab therapy and remains in remission on maintenance treatment. This case highlights the diagnostic challenge of isolated splenomegaly and underscores the importance of splenectomy for both diagnosis and cytoreduction when noninvasive tests are inconclusive. Rituximab immunotherapy can achieve disease control in low-tumor-burden FL, though vigilant long-term follow-up is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.